181 related articles for article (PubMed ID: 36115844)
21. Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors.
Zhang J; Lodish HF
Blood; 2004 Sep; 104(6):1679-87. PubMed ID: 15166036
[TBL] [Abstract][Full Text] [Related]
22. Ras- and Raf-induced down-modulation of non-muscle tropomyosin are MEK-independent.
Janssen RA; Veenstra KG; Jonasch P; Jonasch E; Mier JW
J Biol Chem; 1998 Nov; 273(48):32182-6. PubMed ID: 9822696
[TBL] [Abstract][Full Text] [Related]
23. Leucine-enriched amino acids maintain peripheral mTOR-Rheb localization independent of myofibrillar protein synthesis and mTORC1 signaling postexercise.
Hannaian SJ; Hodson N; Abou Sawan S; Mazzulla M; Kato H; Matsunaga K; Waskiw-Ford M; Duncan J; Kumbhare DA; Moore DR
J Appl Physiol (1985); 2020 Jul; 129(1):133-143. PubMed ID: 32525432
[TBL] [Abstract][Full Text] [Related]
24. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival.
Steinbrunn T; Stühmer T; Gattenlöhner S; Rosenwald A; Mottok A; Unzicker C; Einsele H; Chatterjee M; Bargou RC
Blood; 2011 Feb; 117(6):1998-2004. PubMed ID: 21149634
[TBL] [Abstract][Full Text] [Related]
25. Amino acid-dependent control of mTORC1 signaling: a variety of regulatory modes.
Takahara T; Amemiya Y; Sugiyama R; Maki M; Shibata H
J Biomed Sci; 2020 Aug; 27(1):87. PubMed ID: 32799865
[TBL] [Abstract][Full Text] [Related]
26. The GATOR-Rag GTPase pathway inhibits mTORC1 activation by lysosome-derived amino acids.
Hesketh GG; Papazotos F; Pawling J; Rajendran D; Knight JDR; Martinez S; Taipale M; Schramek D; Dennis JW; Gingras AC
Science; 2020 Oct; 370(6514):351-356. PubMed ID: 33060361
[TBL] [Abstract][Full Text] [Related]
27. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
Wee S; Jagani Z; Xiang KX; Loo A; Dorsch M; Yao YM; Sellers WR; Lengauer C; Stegmeier F
Cancer Res; 2009 May; 69(10):4286-93. PubMed ID: 19401449
[TBL] [Abstract][Full Text] [Related]
28. Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.
Malaguarnera R; Chen KY; Kim TY; Dominguez JM; Voza F; Ouyang B; Vundavalli SK; Knauf JA; Fagin JA
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1976-87. PubMed ID: 25029414
[TBL] [Abstract][Full Text] [Related]
29. Phosphorylation of TSC2 by PKC-δ reveals a novel signaling pathway that couples protein synthesis to mTORC1 activity.
Zhan J; Chitta RK; Harwood FC; Grosveld GC
Mol Cell Biochem; 2019 Jun; 456(1-2):123-134. PubMed ID: 30684133
[TBL] [Abstract][Full Text] [Related]
30. Amino Acids in Autophagy: Regulation and Function.
Shen JZ; Wu G; Guo S
Adv Exp Med Biol; 2021; 1332():51-66. PubMed ID: 34251638
[TBL] [Abstract][Full Text] [Related]
31. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
Heard JJ; Phung I; Potes MI; Tamanoi F
BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.
Young A; Lou D; McCormick F
Cancer Discov; 2013 Jan; 3(1):112-23. PubMed ID: 23103856
[TBL] [Abstract][Full Text] [Related]
33. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways.
Wang Y; Xu W; Yan Z; Zhao W; Mi J; Li J; Yan H
J Exp Clin Cancer Res; 2018 Mar; 37(1):63. PubMed ID: 29554968
[TBL] [Abstract][Full Text] [Related]
34. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological and genetic evaluation of proposed roles of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK), extracellular signal-regulated kinase (ERK), and p90(RSK) in the control of mTORC1 protein signaling by phorbol esters.
Fonseca BD; Alain T; Finestone LK; Huang BP; Rolfe M; Jiang T; Yao Z; Hernandez G; Bennett CF; Proud CG
J Biol Chem; 2011 Aug; 286(31):27111-22. PubMed ID: 21659537
[TBL] [Abstract][Full Text] [Related]
36. TRIM37 deficiency induces autophagy through deregulating the MTORC1-TFEB axis.
Wang W; Xia Z; Farré JC; Subramani S
Autophagy; 2018; 14(9):1574-1585. PubMed ID: 29940807
[TBL] [Abstract][Full Text] [Related]
37. cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity.
Xie J; Ponuwei GA; Moore CE; Willars GB; Tee AR; Herbert TP
Cell Signal; 2011 Dec; 23(12):1927-35. PubMed ID: 21763421
[TBL] [Abstract][Full Text] [Related]
38. Mammalian target of rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein-protein interactions for substrate recognition.
Dunlop EA; Dodd KM; Seymour LA; Tee AR
Cell Signal; 2009 Jul; 21(7):1073-84. PubMed ID: 19272448
[TBL] [Abstract][Full Text] [Related]
39. PDK4 protein promotes tumorigenesis through activation of cAMP-response element-binding protein (CREB)-Ras homolog enriched in brain (RHEB)-mTORC1 signaling cascade.
Liu Z; Chen X; Wang Y; Peng H; Wang Y; Jing Y; Zhang H
J Biol Chem; 2014 Oct; 289(43):29739-49. PubMed ID: 25164809
[TBL] [Abstract][Full Text] [Related]
40. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.
Steinbrunn T; Stühmer T; Sayehli C; Chatterjee M; Einsele H; Bargou RC
Br J Haematol; 2012 Nov; 159(4):430-40. PubMed ID: 22985491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
